INTRODUCTION

Recent advances in cancer immunotherapy, particularly immune checkpoint blockade therapy, have dramatically changed the therapeutic strategy against advanced malignancies [1]. Yet, only a subset of patients demonstrates a positive response to such therapy. Moreover, questions relating to how we can maintain durable clinical responses or how we can successfully treat a broader range of cancers by immunotherapy remain largely unsolved.

Growing evidences suggest that the major barrier to more successful cancer immuno/chemotherapy is the tumor microenvironment (TME), where chronic inflammation has a predominant role in tumor survival and proliferation, angiogenesis and immunosuppression [2–5]. Since our understanding of cancer-related inflam-
information has significantly evolved, we have now various therapeutic options tailored to the TME [6]. These therapeutic strategies include inhibiting inflammatory mediators or their downstream signaling molecules, blocking the recruitment of myeloid cells, modulating immunosuppressive functions in myeloid cells and reeducating the TME [7].

So far, no conclusive studies have been published on stromal content and prognosis in human breast cancer [8]. In an effort to integrate the effects of the TME and patient outcome into pathological criteria, it has been reported that a “reactive” stromal phenotype may predict breast cancer subtypes with an excellent prognosis [9].

Accordingly, the lowest risk tumors were more likely to have high intra-tumoral stromal volume-density and high expression of stromal proteins, including alpha-smooth muscle actin (alpha-SMA), an actin isoform that marks myofibroblasts and cancer associated fibroblasts. Collagens are also critical components of the extra-cellular matrix (ECM) that regulates tumor progression. Although most research on collagen in breast cancer was focused on type I collagen (Col 1) and its pro-carcinogenic effects [10–12], new evidence suggest that a related fibrillar type III collagen (Col 3) plays an important role in suppressing primary tumor growth and metastasis in a murine model of triple-negative breast cancer [13, 14]. However, the role of Col 3 as a co-stimulatory molecules for lymphocytes has not been investigated. While ECM represents a physical barrier to immune cell infiltration, it also provides the substratum essential to the interstitial migration of immune cells [15, 16].

The role which p62/SQSTM1 plays in cancer and tumor stroma cells is a subject of active research [17–20]. A human p62-encoding plasmid was originally proposed as a classic DNA vaccine eliciting adaptive immune response against the p62/SQSTM1 protein over-expressed in cancer cells [21, 22]. However, the history of science and medicine bears multiple examples when a new phenomenon was explained based on the mechanisms which were most popular at the time they were observed, later turning out to be secondary or insignificant [23]. Thus, the mechanism of action of the p62 plasmid needs to be reassessed based on the latest observations. Indeed, although treatment with the p62-encoding plasmid was reported as therapeutically beneficial in dogs with spontaneous mammary tumors [24], it turned out later that unlike in humans, most aggressive canine breast tumors show very low or nil p62 expression [25]. In other word, eliciting an anti-p62 adaptive immunity cannot be the only effect of p62-encoding plasmid.

We have already shown that the p62 DNA treatment dramatically impacted the histopathological characteristics of the malignant lesions. Indeed, following p62 DNA injections, the original solid tumors appear now as multi-lobate neoplasms, separated and sur-rounded by thick bands of inflamed fibrous connective, containing scattered aggregates of macrophages, increased number of CD3+ intratumoral T-lymphocytes (TIL), and plasma cells. [24]. Taken together, this data raises the question of whether p62 plasmid can alter the TME in a way favorable for anti-cancer immune response.

Another line of research revealed that administering the p62 plasmid reduces systemic chronic inflammation in rodent models resulting in the prevention and / or alleviation of a number of diseases. For example, the plasmid reduced metabolic syndrome induced by a high caloric high fat Western diet [26] an effect on this disease that may be linked to anticancer effects [27]. Osteoporosis is also a disorder pertaining to chronic inflammation which shares common signaling pathways with cancer (e.g., RANK/RANKL signaling) [28]. The p62 plasmid demonstrated both preventive and therapeutic effects in a mouse model of ovariectomy-induced osteoporosis with an effect on pro-inflammatory cytokines and RANK/RANKL signaling [29]. Also, p62 DNA has been reported to delay the development of age-related macular degeneration (AMD) in rapidly aging OXYS rats [30], which may constitute another example of the anti-inflammatory effects.

Like in humans, canine spontaneous mammary carcinomas are very heterogeneous in terms of morphology and biological behavior [31]. Simple and complex carcinomas are recorded as the most common types of mammary malignances [32, 33]. Solid and tubulopapillary mammary carcinomas reveal both histological and molecular homology to human breast carcinomas [34]. Of note, in both canine mammary tumors and in human prostate cancer, the number of intratumoral T-lymphocytes is reported to be higher in benign lesions than in their malignant counterparts [35, 36]. Thus, testing the effect(s) of a cancer treatment on canine model may provide valuable comparative oncology clues.

RESULTS

Anti-tumor activity of p62 DNA and histopathological features

The anti-tumor effects of p62 DNA has been evaluated in a cohort of six (6) dogs bearing simple mammary tumors (Table 1). As shown in Table 2, the new trial confirms previous results [24] with p62 DNA-treated
Table 1. Patients characterization.

| Pt# | Breed       | Age (yrs) | Type | WHO Stage |
|-----|-------------|-----------|------|-----------|
| 1   | German Seph.| 11        | SCa  | T3-N0-M0  |
| 2   | Mongrel     | 10        | TP Ca| T1-NO-MO  |
| 3   | German Seph.| 8         | SCa  | T3-N2-M1  |
| 4   | Poodle      | 14        | SCa  | T2-N1-M0  |
| 5   | Breton      | 10        | TP Ca| T1-N0-M0  |
| 6   | Boxer       | 10        | TP Ca| T2-N0-M0  |

Lesion types: SCa, solid carcinoma; TP Ca, Tubo-papillary carcinoma.

Table 2. p62 DNA antitumor activity.

| Pts # | Dose × injection (mg) | # injections | Initial | Final | Change Tumor volum. (%) | Mastectomy |
|-------|-----------------------|--------------|---------|-------|-------------------------|------------|
| 1     | 0.75                  | 9            | 8.6 × 6.2| 6.4 × 3.4| −78                     | YES        |
| 2     | 0.75                  | 3            | 1.1 × 0.7| 0.5 × 0.6| −66                     | YES        |
| 3     | 1.5                   | 9            | 20 × 16  | 19× 12 | −75                     | YES        |
| 4     | 1.5                   | 3            | 2.7 × 3.5| 2.7 × 2.7| −40                     | YES        |
| 5     | 0.75                  | 9            | 4.9 × 3.5| 3×3    | −55                     | NO         |
| 6     | 0.75                  | 9            | 3.2 × 1.8| 2×2    | −23                     | YES        |

Table 2. p62 DNA antitumor activity.

patients showing a marked reduction of the sizes of their neoplastic masses without complete tumor eradication. Next, microscopic examinations revealed that p62 DNA induced a remarkable infiltration of inflammatory/immunocells in the original tumors, never observed in untreated dogs, nor in patients injected with the irrelevant (sham) pcDNA3.1 plasmid (See Supplementary Figure 1A, 1B). Histopathological changes observed after p62DNA injections, are summarized in Table 3. Two patients (# 4 and #6) demonstrated the switching of their tumor histotypes from simple high malignant lesions to less aggressive complex carcinoma. In one patient (#5), a low malignant tubulopapillary carcinoma reverted to adenoma. Patient #1 showed a transition from solid to tubulo-papillary histotype, while in patient (# 3) the residual tumor maintained the same histotype and grade as that of the original lesion. Importantly, all p62-treated patients, are still tumor and metastasis-free and maintain good quality of life 4 years after surgery (mastectomy).

p62 DNA up-regulates alpha-SMA and type III collagen expression

Upregulated expression of alpha-SMA and / or Col 3 is associated with a good prognosis in breast cancer [9, 13, 14]. We utilized immunohistochemistry to test if their levels change in response to p62 DNA treatment re-organizing the tumor microenviornement and making it more favorable to anti-cancer immunoresponse. Indeed we observed that p62 DNA administration induced strong increase in the expression of stromal alpha-SMA (Figure 1) coupled with a robust synthesis and deposition of Col 3 in the ECM, as opposed to a next to basal expression of Col 1 (Figure 2). On the other hand, both Col 1 and Col 3 levels are minimal in a normal mammary gland (Figure 3).

The adaptive immune system is essential for the anti-cancer effect of p62 plasmid

We reported that in dogs p62 treatment increases the number of TILs [24]. However, in canine spontaneous tumors we cannot establish if an adaptive immune system is essential for the antitumor effect of p62 plasmid. Moreover, we know already that eliciting a specific anti-p62 immunity cannot be the only mechanism for the plasmid anti-cancer activity, since canine cancer cells (unlike human ones) omit p62 during tumor progression [25]. To bring these two facts together, we hypothesized that p62 potentiates the effects of T-cells targeting cancer antigens other than p62 (e.g., acting via immunomodulatory mechanisms). If that is correct, p62 plasmid would increase the efficiency of any other therapy generating T-cells targeting tumor associated antigens (e.g., immunotherapies).

The above presented data made two option equally plausible. The first hypothesis would state that p62 plasmid induce the re-organization of the tumor stroma, and this change(s) is sufficient for the antitumor effect of
Table 3. Tumor histotypes / grades before and after p62 DNA treatment.

| Pts# | Before | MS  | After | MS*  |
|------|--------|-----|-------|------|
| 1    | SC     | +++ | TP    | ++   |
| 2    | TP     | ++  | TP    | +    |
| 3    | SC     | +++ | SC    | +++  |
| 4    | SC     | +++ | CC    | ++   |
| 5    | TP     | +   | TPA   |      |
| 6    | TP     | +++ | CC    | +    |

TP: tubulo-papillary carcinoma; CC: complex carcinoma; TPA: tubulo-papillary adenoma.

*MS (Malignancy Score) as obtained by combining WHO Stage and grading 32: (+++), high; (++), middle; (+), low.

![Image of IHC staining of alpha-SMA](A) Before (B) After p62 DNA treatment (20×).

Figure 1. IHC staining of alpha-SMA in the tumor stroma before (A) and after (B) p62 DNA treatment. (20 ×).

![Image of IHC evaluation of Col 1 and Col 3 expression](A) Before (B) After (C) p62 DNA injections (20×).

Figure 2. IHC evaluation of Col 1 (A, C) and Col 3 expression (B, D) in tumor biopsies, before (A, B) and after (C, D) p62 DNA injections (20×).
the plasmid. An alternative hypothesis would state that p62 plasmid acts primarily via adaptive immunity. If the first hypothesis is correct, the antitumor effects would be the same both in wild-type mice or in syngeneic mice with severe combined immunodeficiency (SCID) SCID mice have a genetically inactivated adaptive immune system (i.e. lacking T- and B-cells), but maintain an intact innate immune system (i.e., macrophages, NK cells etc). As depicted in Figure 4, when SCID mice were challenged with B16 melanoma cells, they developed tumors similar to control (wt) mice, indicating that the lack of an adaptive immune system does not promote tumor development in this model. However, in contrast to wt mice, the p62 plasmid lost its ability to inhibit tumor growth in SCID animals (Figure 4). Furthermore, whereas p62 DNA increased survival in wt mice, no such effect was seen in SCID mice (Figure 5). Thus, we conclude that an adaptive immune system is required for the anti-cancer of the p62 plasmid. Finally to test if the p62DNA can enhance the effects of other immuno-therapies, we employed a model of adaptive cell transfer, where T-cells from tumor-bearing mice are transferred to animals with established tumor (or metastasis). In this model, the p62 plasmid was administered on days 9 and 14 after the animals received the transplantable tumor, one week before the mice were sacrificed. The days of plasmid administration left us time period to short to develop a protective anti-p62 immunity which could block / reduce the formation of lung metastasis. As shown in Figure 6, while p62DNA alone shows only a minor effect on lung metastasis, it amplified the anti-metastatic effects of transferred T-cells.

DISCUSSION

The present translational oncological study was stimulated by the observations made during phase I / Ila clinical trials of patients with advanced ovarian and breast cancer. We reported transient increase in progression-free survival in a majority of patients, and a partially restored sensitivity to chemotherapy in all patients treated with the p62 plasmid [37]. Although the causes behind the development of drug resistance include different mechanisms [38], growing evidence indicates that changes in tumor microenvironment may contribute to resistance against chemo and radio-therapies [39]. It is a commonly accepted view that the lower the grade of a tumor is, the more sensitive the tumor would be to a therapy. The results of the present paper demonstrate that the treatment with the p62 DNA induces dramatic stromal alterations reverting a tumor grade towards less aggressive lesions. If the same phenomenon takes place in humans, it would explain why the p62-treated patients became responsive to chemotherapy.

As reported before [9], building up a “reactive” stromal phenotype characterized by alfa-SMA and Col 3 accumulation can constrain tumor growth. Our results (Figures 1–3) demonstrate that p62 DNA administration lead to increased intratumoral expression of both proteins.

Indeed, Col 3 expression levels were greatly increased in tumor ECM of treated dogs. At the same time, the fact that Col 1 was not upregulated to the same extent may not be too surprising. For example, it is known that matrix metalloproteinase cleaves Col I while Col 3 level increases [40]. Similarly, it was reported that TNF-alfa, a major pro-inflammatory cytokine, down-regulates stromal alfa-SMA [40]. On the other hand, we previously demonstrated that p62 DNA quenches an ovariectomy-induced increase of TNF-alfa levels [29]. Thus, our observations support the hypothesis that p62 plasmid drives a stroma re-programming towards tumor suppression and increasing therapeutic vulnerability.

Figure 3. IHC of normal a mammary gland (NMG) showing both Col1 (A) and Col 3 (B) basal expression levels (brown dots). Bars, 50 µm.
Remodeling of the ECM may partially explain the increased number of T-lymphocytes we observed in canine tumors following p62 plasmid treatment [24]. It was suggested that the trafficking and motility of T lymphocytes is guided by collagen fibers [41]. Thus, by creating a network of EMC fibers throughout the tumor, p62-DNA could promote axis of collagen alignment, which T cells can move along. According to a recently-stipulated hypothesis, ECM composition could define collective cooperated lymphocyte motility as opposed to an individual trafficking of the cells [42]. Although this hypothesis was suggested for B-lymphocytes only, it would be interesting to test if the same takes place for T-lymphocytes, and whether the p62 plasmid induces such collective lymphocyte tumor penetration.

Despite all the facts linking the extracellular matrix to TILs, it remained to be possible that treatment with the p62 plasmid acts on cancer cells through a mechanism not involving an adaptive immune response. For example, it
was reported [13] that reduced Col 3 level in heterozygous mice led to increased tumor formation in vivo when the mice were challenged with transplantable breast cancer model. In vitro data from the same paper suggested that the metastatic process is significantly increased when Col 3 level is reduced. The later phenomenon could not be due to TLC engagement because the in vitro system did not contain lymphocytes.

To establish whether the p62 plasmid indeed acts via an anti-tumor adaptive immune response, we compared the anti-tumor effect of the p62 plasmid in wt and SCID mice strains. Indeed, if the plasmid acts on the cancer cells directly and/or via a mechanism other than an adaptive immune response then the B16 melanoma administered to the two strains would demonstrate the same sensitivity to the plasmid. In contrast, if the plasmid acts via stimulating/modulating an adaptive immune response, it would be inactive in SCID mice lacking the lymphocytes. The later turned out to be the case. Although p62 DNA has reduced the growth of the subcutaneous B16 melanoma tumor and increased the rate of survival in the wt animals, the plasmid was completely inactive in SCID mice. Thus, we conclude that p62 DNA acts via adaptive immune system.

Because canine mammary tumors, contrary to human tumors, do not express p62 [25], the plasmid could not act as a classic DNA vaccine encoding p62 as a target tumor-specific antigen. Thus, we hypothesized that p62 DNA enhances the adaptive immune response to tumor antigens other than p62. To test this hypothesis we conducted an adoptive T-cell transfer experiment. T-lymphocytes were isolated from mice challenged with transplantable tumor models and, propagated ex vivo, were administered to animals bearing the same tumors. Obviously an absolute majority of transferred T-cells were targeted against tumor antigens other than p62. This led to a significant but incomplete reduction of the number of tumor lesions in the lungs. Now we could test if supplementing T-cell transfer with p62 plasmid would lead to a greater protective effect that T-cell transfer alone. The murine cancer model is not p62 negative. However, we administered p62 DNA at late time points, so the animals did not have enough time to develop a protective anti-p62 immune response which could influence the formation of tumor lesions in lungs. According to our experience, this type of antigenic affect would take at least 3 weeks. Nevertheless, we observed that treatment with the p62 plasmid enhanced effects of adaptive T-cell transfer. We interpret this result as the ability of injected p62 plasmid to enhance the anti-cancer effect of T-lymphocytes targeted against non-p62 antigenic cancer epitopes. The fact that the p62 plasmid acts via an adaptive immune response well corresponds to the observations that the plasmid restores sensitivity to chemotherapy. Despite the fact that originally chemotherapeutic agents were selected based their ability to kill rapidly dividing cells, it turned out that many of them act via the immune system (e.g. stimulating immune-presenting cell death or regulating T-reg) [43, 44]. Thus, the result of chemotherapy is a lymphocyte attack on cancer cells. Creating a tumor microenvironment favorable for active TILs makes p62 DNA an equally promising adjuvant for immune-, chemo- and radiation therapies because all of them involve immune response.

CONCLUSIONS

While acknowledging that a sizable clinical study is necessary to evaluate if the results we observed on a limited sample size are representative for dogs of different ages and breeds, this pilot investigation lead us to propose that p62 DNA treatment can reprogram tumor stroma. The plasmid can be used as an adjuvant for cancer therapies directly and/or indirectly acting through an immune response (such as chemotherapeutics).

MATERIALS AND METHODS

p62 DNA plasmid

Human p62 (Sqstm1, isoform 1) – encoding plasmid was described elsewhere [37] and produced endotoxin Free-GMP grade by the Aldevron (ND, USA). Endotoxin-free pcDNA3.1 plasmid was prepared by alkaline lysis using Endo Free Plasmid Kit (Qiagen).

Dogs patients and treatment

Assessment of the therapeutic effect was performed in veterinary clinic of the University of Camerino (Italy). A total of six dogs, all females, of different breeds and ages were enrolled in the study (Table 1). All of them had histologically confirmed diagnosis of mammary carcinoma with WHO stages I-III, progressive disease. p62 DNA was administered i.m. once a week at the doses of 0.75, 1.5 mg for 3–9 weeks (Table 1). During the treatment, blood samples were collected, and the tumors sizes / volumes were weekly measured with calipers according to formula \( \pi /6 \times L \times W \times H \). The weight and overall well-being of patients were monitored. All the treatments were performed with full consent of the owners.

Tumor specimens and immunohistochemistry

Biopsies (Trucut) were performed in all dogs before treatment to establish initial diagnosis. In 5 out of 6 patients, a second biopsy, along with samples from
Resected tumors (mastectomy) were collected. Patients #5 had no mastectomy (see Text). The samples, fixed in 10% neutral buffered formalin, were subjected to histological and immunohistochemical analysis. For each sample 4 μm-thick sections were obtained; one section was stained with haematoxylin-eosin, the other was used for the immunohistochemical analysis. The samples were histologically classified and graded according to criteria of Goldschmidt et al. [32].

For immunohistochemistry, sections were mounted on Superfrost®Plus slides and an avidin–biotin–peroxidase-complex (ABC) technique with diaminobenzidine as the chromogen was performed to evaluate the antigen expression. To investigate stromal and ECM responses after p62 plasmid administration, sections were incubated with the following antibodies: mouse monoclonal anti-alpha SMA (1:50; Sigma Aldrich, S. Luis, Missouri USA); rabbit polyclonal anti Collagen type 1 (1:75; Novocastra, Newcastle, UK); mouse monoclonal anti- Collagen type III (Abcam, Cambridge, UK). Sections were counter-stained in Mayer’s haematoxylin.

Mice and tumor growth assessment

C57BL/6J mice were control (wt) animals, and immunodeficient B6. CB17- Prkdcscid/SzJ (C57BL/6 scid). All mice (females 6–8 weeks,18–20 g) were from Jackson Lab (Bar Harbor, ME, USA). Mice (15 per group) were inoculated with B16 melanoma (3 × 10^5 in 0.1 ml of PBS) s.c. in right femurs and injected with p62 plasmid (300 ug/mouse i.m in 0.1 ml of saline), or saline (0.1 ml) as a control on days 1, 8, 15 after tumor inoculation. Our previous experiments demonstrated that sham vector (pcDNA3.1) had no effect on tumor growth (FMV unpublished observation). Tumor growth was monitored every other day by a caliper as indicated above. Statistical analysis was performed by two-way ANOVA with Bonferroni post-tests.

Tumor-draining lymph nodes (TDLN) T cells for adoptive immunotherapy

C57BL/6J mice were inoculated subcutaneously with 1 × 10^6 MCA205 fibrosarcoma cells in both flanks. Twelve days later, inguinal TDLNs (tumor-draining lymph node) were harvested, and single-cell suspensions were prepared and culture-activated with anti-CD3 antibody and IL-2 as described [45]. Four days later, TDLN cells were resuspended in Hanks’ balanced salt solution (HBSS) for adoptive immuno-therapy [46, 47]. Therapeutic efficacy of transferred T effector cells was assessed in the treatment of 9-day established MCA205 pulmonary metastases by intravenous injection of 5 × 10^6 culture-activated T cells to each mouse and / or p62 plasmid (300 ug/mouse i.m) on days 9 and 14. To improve the therapeutic efficacy of transferred T cells, tumor-bearing mice were pretreated intravenously with cyclophosphamide (100 mg/kg) 1 day before T cells infusion [48].

Assessment of antitumor effect

For establishment of pulmonary metastases, C57BL/6J mice were injected intravenously with 3 × 10^5 MCA205 suspended in 200 ul of HBSS. On day 26 after inoculation, MCA205 tumor-bearing lungs were counterstained with India ink and were enumerated. Lungs with more than 250 nodules were assigned >250 as the maximum number that can be counted reliably.

ACKNOWLEDGMENTS

The authors would like to thank prof. Michael Sherman for intellectually stimulating discussions and editorial comments.

CONFLICTS OF INTEREST

Franco M.Venanzi, Vladimir Gabai, and Alexander Shneider are employees of CureLab Oncology Inc. and have financial interest in this company. All other authors have no conflicts of interests.

REFERENCES

1. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018; 62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001 PMID:29990692
2. Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015; 36:1085–93. https://doi.org/10.1093/carcin/bgv123 PMID:26354776
3. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 2009; 8:2005–13. https://doi.org/10.4161/cc.8.13.8985 PMID:19550141
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357:539–45. https://doi.org/10.1016/S0140-6736(00)04046-0 PMID:11229684
5. Motz GT, Coukos G. The parallel lives of angiogenesis
and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011; 11:702–11. https://doi.org/10.1038/nri3064 PMID:21941296

6. Puré E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res. 2016; 4:269–78. https://doi.org/10.1158/2326-6066.CIR-16-0011 PMID:27036971

7. Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018; 15:366–381. https://doi.org/10.1038/s41571-018-0007-1 PMID:29651130

8. Cid S, Eiro N, Fernández B, Sánchez R, Andicoechea A, Fernández-Muñiz PJ, González LO, Vizoso FJ. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes. Clin Breast Cancer. 2018; 18:e123–e133. https://doi.org/10.1016/j.clbc.2017.08.008 PMID:28927692

9. Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin Cancer Res. 2016; 22:5068–5078. https://doi.org/10.1158/1078-0432.ccr-16-0171 PMID:27768885

10. Moscat J, Karin M, Diaz-Meco MT. p62 in Cancer: Signaling Adaptor Beyond Autophagy. Cell. 2016; 167:506–609. https://doi.org/10.1016/j.cell.2016.09.030 PMID:27768885

11. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008; 6:11. https://doi.org/10.1186/1741-7015-6-11 PMID:18442412

12. Kakkad SM, Solaiyappan M, Argani P, Sukumar S, Jacobs LK, Leibfritz D, Bhujwalla ZM, Glunde K. Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt. 2012; 17:116017. https://doi.org/10.1117/1/JBO.17.11.116017 PMID:23117811

13. Brisson BK, Mauldin EA, Lei W, Vogel LK, Power AM, Lo A, Dopkin D, Khanna C, Wells RG, Puré E, Volk SW. Type III Collagen Directs Stromal Organization and Limits Metastasis in a Murine Model of Breast Cancer. Am J Pathol. 2015; 185:1471–86. https://doi.org/10.1016/j.ajpath.2015.01.029 PMID:25795282

14. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 2008; 88:591–601. https://doi.org/10.1038/labinvest.2008.31 PMID:18414401

15. Rao WH, Hales JM, Camp RD. Potent costimulation of effector T lymphocytes by human collagen type I. J Immunol. 2000; 165:4935–40. https://doi.org/10.4049/jimmunol.165.9.4935 PMID:11046019

16. Dustin ML, de Fougerolles AR. Reprogramming T cells: the role of extracellular matrix in coordination of T cell activation and migration. Curr Opin Immunol. 2001; 13:286–90. https://doi.org/10.1016/S0952-7915(00)00217-X PMID:11406359

17. Goruppi S, Clocchiatti A, Dotto GP. A role for stromal autophagy in cancer -associated fibroblast activation. Autophagy. 2019; 15:738–739. https://doi.org/10.1080/15548627.2019.1569936 PMID:30499183

18. Venanzi F, Shifrin V, Sherman M, Gabai V, Kiselev O, Komissarov A, Grudinin M, Shartukova M, Romanovskaya-Romanko EA, Kudryavets Y, Bezdenezhnykh N, Lykhova O, Semesyuk N, et al. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget. 2013; 4:1829–35. https://doi.org/10.18632/oncotarget.1397 PMID:24121124

22. Gabai VL, Shifrin VI. Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol. 2014; 33:375–82. https://doi.org/10.3109/08830185.2014.954699
23. Shneider AM. Mental inertia in the biological sciences. Trends Biochem Sci. 2010; 35:125–28. https://doi.org/10.1016/j.tibs.2009.12.004 PMID:20093032

24. Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chrusov A, Latanova A, Shcherbinina V, Shifrin V, Shneider A. Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget. 2014; 5:12803–10. https://doi.org/10.18632/oncotarget.2516 PMID:25296974

25. Mariotti F, Magi GE, Gavazza A, Vincenzetti S, Komissarov A, Shneider A, Venanzi FM. p62/SQSTM1 expression in canine mammary tumours: Evolutionary notes. Vet Comp Oncol. 2019; 17:570–577. https://doi.org/10.1111/vco.12523 PMID:31332942

26. Halenova T, Savchuk O, Ostapchenko L, Chursov A, Fridlyand N, Komissarov AB, Venanzi F, Kolesnikov SI, Sufianov AA, Sherman MY, Gabai VL, Shneider AM. P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions. Oncotarget. 2017; 8:56030–56040. https://doi.org/10.18632/oncotarget.19840 PMID:28915571

27. Ecker BL, Lee JY, Sterner CJ, Solomon AC, Pant DK, Shen F, Peraza J, Vaught L, Mahendra S, Belka GK, Pan TC, Schmitz KH, Chodosh LA. Impact of obesity on breast cancer recurrence and minimal residual disease. Breast Cancer Res. 2019; 21:41. https://doi.org/10.1186/s13058-018-1087-7 PMID:30867005

28. Renema N, Navet B, Heymann MF, Lezot F, Heymann D. RANK-RANKL signalling in cancer. Biosci Rep. 2016; 36. https://doi.org/10.1042/BSR20160150 PMID:27729652

29. Sabbieti MG, Agas D, Capitani M, Marchetti L, Concetti A, Vullo C, Catone G, Gabai V, Shifrin V, Sherman MY, Shneider A, Venanzi FM. Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent. Oncotarget. 2015; 6:3590–9. https://doi.org/10.18632/oncotarget.2884 PMID:25668818

30. Kolosova NG, Kozhevnikova OS, Telegina DV, Fursova AZ, Stefanova NA, Muraveva NA, Venanzi F, Sherman MY, Kolesnikov SI, Sufianov AA, Gabai VL, Shneider AM. p62 /SQSTM1 coding plasmid prevents age related macular degeneration in a rat model. Aging (Albany NY). 2018; 10:2136–47. https://doi.org/10.18632/aging.101537 PMID:30153656

31. http://www.vetcancergroup.com/clients/15753/documents/canine_mammary_tumors.pdf

32. Goldschmidt M, Peña L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol. 2011; 48:117–31. https://doi.org/10.1177/0300985810393258 PMID:21266722

33. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol. 2005; 133:246–52. https://doi.org/10.1016/j.jcpa.2005.05.003 PMID:16202421

34. Liu D, Xiong H, Ellis AE, Northrup NC, Rodriguez CO Jr, O’Regan RM, Dalton S, Zhao S. Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. Cancer Res. 2014; 74:5045–56. https://doi.org/10.1158/0008-5472.CAN-14-0392 PMID:25082814

35. Carvalho MI, Pires I, Prada J, Queiroga FL. T-lymphocytic infiltrate in canine mammary tumours: clinical and prognostic implications. In Vivo. 2011; 25:963–69. PMID:22021690

36. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol. 2009; 86:108–13. https://doi.org/10.1016/j.yexmp.2008.11.010 PMID:19111537

37. Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zryyanov AV, Burkanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, et al. Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget. 2017; 8:53730–53739. https://doi.org/10.18632/oncotarget.16574 PMID:28881846

38. Leary M, Heerboth S, Lapinska K, Sarkar S. Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. Cancers (Basel). 2018; 10. https://doi.org/10.3390/cancers10120483 PMID:30518036

39. Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Gumiński A. Role of intra- tumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012; 4:675–84. https://doi.org/10.1002/emmm.201101131 PMID:22733553

40. Klaus V, Tanios-Schmies F, Reep C, Trenner M,
Matevosssian E, Eckstein HH, Pelisek J. Association of Matrix Metalloproteinase Levels with Collagen Degradation in the Context of Abdominal Aortic Aneurysm. Eur J Vasc Endovasc Surg. 2017; 53:549–58. https://doi.org/10.1016/j.ejvs.2016.12.030 PMID:28209269

41. Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW, Schneck JP, Gerecht S. Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes. Matrix Biol. 2019. [Epub ahead of print]. https://doi.org/10.1016/j.matbio.2019.02.003 PMID:30776427

42. Rey-Barroso J, Calovi DS, Combe M, German Y, Moreau M, Canivet A, Wang X, Sire C, Theraulaz G, Dupré L. Switching between individual and collective motility in B lymphocytes is controlled by cell-matrix adhesion and inter-cellular interactions. Sci Rep. 2018; 8:5800. https://doi.org/10.1038/s41598-018-24222-4 PMID:29643414

43. Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K, Bridgeman H, Adams R, Brewster A, Jones R, Gwynne S, Blount D, Harrop R, Hills R, Gallimore A, Godkin A. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clin Cancer Res. 2017; 23:6771–6780. https://doi.org/10.1158/1078-0432.CCR-17-0895 PMID:2885352

44. Inoue S, Setoyama Y, Odaka A. Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model. Exp Ther Med. 2014; 7:703–08. https://doi.org/10.3892/etm.2014.1489 PMID:24520271

45. Kjaergaard J, Shu S. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol. 1999; 163:751–59. PMID:10395677

46. Kjaergaard J, Peng L, Cohen PA, Shu S. Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin Immunol. 2003; 108:8–20. https://doi.org/10.1016/S1521-6616(03)00090-1 PMID:12865066

47. Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, Thayer M, Rodig S, Kutok JL, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015; 7:277ra30. https://doi.org/10.1126/scitranslmed.aaa1260 PMID:25739764

48. Hughes E, Scurr M, Campbell E, Jones E, Godkin A, Gallimore A. T-cell modulation by cyclophosphamide for tumour therapy. Immunology. 2018; 154:62–68. https://doi.org/10.1111/imm.12913 PMID:29460448

49. Narayanan AS, Clagett JA, Page RC. Effect of Inflammation on the of Collagen Types, I, III, IV, and V and Type I Trimer and Fibronectin in Human Gingivae. J Dent Res. 1985; 64:1111–16. https://doi.org/10.1177/002203458506400090201

50. Mattyasovszky SG, Hofmann A, Brochhausen C, Ritz U, Kuhn S, Wollstäder J, Schulze-Koops H, Müller LP, Watzek B, Rommens PM. The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts. Arthritis Res Ther. 2010; 12:R4. https://doi.org/10.1186/ar2902 PMID:20064200
Supplementary Figure 1. Histological examination of solid carcinomas (A and B) 7 weeks after treatment with DNA plasmids. (A) p62 DNA (Injection dose-1.5mg: #5 injection). (B) pcDNA3.1 sham vector (Injection dose-1.5mg: #5 injection). Bars, 50 µm.